10x Genomics, Inc. (TXG)
- Previous Close
27.52 - Open
26.93 - Bid 26.87 x 700
- Ask 26.91 x 200
- Day's Range
26.30 - 27.14 - 52 Week Range
26.30 - 63.57 - Volume
1,044,745 - Avg. Volume
1,433,903 - Market Cap (intraday)
3.206B - Beta (5Y Monthly) 1.89
- PE Ratio (TTM)
-- - EPS (TTM)
-2.18 - Earnings Date Apr 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
53.57
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
www.10xgenomics.com1,259
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: TXG
Performance Overview: TXG
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TXG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TXG
Valuation Measures
Market Cap
3.21B
Enterprise Value
2.91B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.09
Price/Book (mrq)
4.33
Enterprise Value/Revenue
4.71
Enterprise Value/EBITDA
-14.20
Financial Highlights
Profitability and Income Statement
Profit Margin
-41.23%
Return on Assets (ttm)
-12.22%
Return on Equity (ttm)
-32.98%
Revenue (ttm)
618.73M
Net Income Avi to Common (ttm)
-255.1M
Diluted EPS (ttm)
-2.18
Balance Sheet and Cash Flow
Total Cash (mrq)
388.7M
Total Debt/Equity (mrq)
12.87%
Levered Free Cash Flow (ttm)
30.63M